APLP2 as a Molecular Link Between Immune Regulation and Bone Metabolism in Hepatocellular Carcinoma: Evidence from scRNA-Seq and Functional Validation
Preprint
- 11 December 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Background and Aims: Hepatocellular carcinoma (HCC) remains a significant health concern worldwide, characterized by elevated mortality rates that are often associated with diagnoses occurring in advanced stages and the restricted efficacy of treatment options currently available. Immune checkpoint inhibitors (ICIs) demonstrate promise in treating HCC; nonetheless, challenges related to therapeutic resistance and varied responses among patients underscore the necessity of identifying new biomarkers and comprehending the fundamental mechanisms involved. This research explores the molecular relationship between immune regulation and bone metabolism in HCC by employing integrated single-cell RNA sequencing (scRNA-seq), bulk transcriptomics, and functional validation. Methods: The analysis of publicly accessible scRNA-seq (GSE223204) and bulk RNA-seq (TCGA-LIHC) datasets was conducted to discover distinct cell subpopulations and signaling patterns. Clustering, ligand-receptor interaction analysis, and transcription factor mapping were performed using the Seurat, CellChat, and SCENIC pipelines. A random survival forest method helped identify important prognostic genes. The research examined how immune cells infiltrate and their relationship with components that regulate the immune response. Clinical HCC samples were obtained for validation using qPCR. The functional effects of the gene APLP2 were studied through small interfering RNA (siRNA) knockdown experiments in HCC cell lines and co-culturing with osteoblasts. Results: In the tissues of HCC, nine distinct cell types were recognized, where hepatocytes demonstrated significant involvement in pathways related to bone metabolism and immune functions. Seven key genes (APLP2, SERPINC1, CAT, PDIA6, SLC2A2, C1S, and CFB) were found to be prognostically significant and closely linked to immune cell infiltration, immunomodulatory checkpoints, and key metabolic signaling pathways, including WNT/β-catenin and PI3K-AKT-mTOR. Particularly, APLP2 showed increased expression specifically in cancerous tissues. Reduced APLP2 levels suppressed proliferation, invasion, migration, and promoted apoptosis in HCC cells. Moreover, the downregulation of APLP2 lessened the suppressive influence of tumor cells on osteoblast differentiation, indicating its potential regulatory function in bone metabolism. Conclusion: This research highlights APLP2 as a new molecular connector between immune evasion and dysregulation of bone metabolism in HCC. The combination of single-cell analysis along with experimental validation offers fresh perspectives on the underlying mechanisms of immunotherapy resistance and emphasizes APLP2 as a promising dual-function therapeutic target.Keywords
All Related Versions
- Version 1, 2025-12-11, Research Square
- Published version: Cancer Cell International, 26 (1).
This publication has 43 references indexed in Scilit:
- Liquid Biopsy in Hepatocellular Carcinoma: ctDNA as a Potential Biomarker for Diagnosis and PrognosisCurrent Oncology Reports, 2025
- The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survivalPancreatology, 2024
- Comprehensive intratumoral heterogeneity landscaping of liver hepatocellular carcinoma and discerning of APLP2 in cancer progressionEnvironmental Toxicology, 2023
- Management of Hepatocellular CarcinomaJAMA Surgery, 2023
- Combination immunotherapy for hepatocellular carcinomaJournal of Hepatology, 2023
- Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapyJournal of Hepatology, 2023
- Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunityImmunity, 2023
- Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classificationHepatology, 2018
- Personalized treatment of patients with very early hepatocellular carcinomaJournal of Hepatology, 2017
- Hepatocellular Carcinoma With Osseous Metaplasia and Bone Marrow ElementsClinical Gastroenterology and Hepatology, 2015